KCHC Annual Report and Accounts 2024-25 Spreads - Flipbook - Page 54
Notes to the financial statements
2.4. Description and structure of funds
a) Restricted funds
Restricted funds are made up of funds where the
income was restricted by the donors for specific
use. This includes income from specific fundraising
appeals. The funds with balances over £100,000 are
listed below:
• The Paediatric Liver Research Laboratories Fund
consists of money donated to enable King’s College
Hospital to build and equip brand new state-of-theart laboratories and learning facilities;
• The David Hughes Special Trust Fund is restricted
to spending on a strategic grants programme
established by the Trustees to support major
developments at King’s College Hospital NHS
Foundation Trust;
• The Transforming Liver Care Fund was established to
raise funds for transforming the care of children with
acute liver disease; and
• Renal Legacy from Spratt, and Paediatric Liver
Research (Flynn)
• Retinal Research Fund was established to support
retinal research.
54
S U P P O R T K I N G S .O R G .U K
c) Unrestricted funds
Unrestricted funds are made up of clinically
designated funds, a designated fund for strategic
grants, development of capital projects, investment
revaluation reserve and general funds.
Donations and legacies are allocated to designated
funds where the donor has given an indication
that they wish the funds to be used for a particular
purpose. There are over 230 clinical designated funds
held by the Charity for different medical specialties
and service areas within the hospital. The value of
the individual funds range from under £1,000 to over
£800,000.
At Mar 31 2025, £2.4m (2024: £4.87m) was held in
a designated fund for strategic grants. The value
is equivalent to the projected level planned to be
invested in strategic projects over the three year
period of the Charity’s strategy
In addition, a fund of £0.97m (2024: £1m) has been set
aside for pump priming major capital projects.
During the year, the Charity transferred £1.15m
loss on investment revaluation to Designated funds
Revaluation Reserve (2024: gain on investment
revaluation of £1.53m), and £139k from Designated
Clinical Funds in respect of Designated Fund Levy
(2024: £nil).
